Matthew Nix

Matthew Nix is a principal scientist in the Immunology Group focused on driving the early-stage development of Cartography’s pipeline of novel CAR-T therapies. Before joining Cartography, Matt conducted research at UCSF in the department of laboratory medicine where he developed a new CAR-T therapy for difficult to treat pediatric leukemia, which is now poised to head to clinical trials at UCSF. He is also an Assistant Adjunct Professor at UCSF, and when he’s not daydreaming about cell therapies and synthetic biology.